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The Neuroendocrine Impact of Chronic Stress on Cancer
AbSTrAcT
Behavioral processes have long been suspected to influence many health processes 
including effects on cancer. However, mechanisms underlying these observations are not 
fully understood. Recent work has demonstrated that chronic behavioral stress results in 
higher levels of tissue catecholamines, greater tumor burden, and a more invasive pattern 
of ovarian cancer growth in an orthotopic mouse model. These effects are mediated 
primarily through the b2 adrenergic receptor (ADRB2) activation of the tumor cell cyclic 
AMP (cAMP)‑protein kinase A (PKA) signaling pathway. Additionally, tumors in stressed 
animals have increased vascularization and enhanced expression of vascular endothelial 
growth factor (VEGF) and matrix metalloproteinases (MMPs) ‑2 and ‑9. In this review, 
we highlight the importance of the neuroendocrine stress response in tumor biology and 
discuss mechanisms by which the b‑adrenergic receptors on ovarian cancer cells enhance 
angiogenesis and tumor growth.
InTroducTIon
Over twenty-five years ago, Engel recognized that biological factors alone cannot account 
for all changes in physical health and that social and behavioral dimensions must also be 
considered.1 In clinical and epidemiological studies, cancer progression, and to a lesser 
extent, cancer onset have been related to chronic stress, depression, lack of social support 
and other psychological factors.2-6 Stress is a complex process encompassing environmental 
and psychosocial factors and initiates a cascade of information-processing pathways in both 
the central and peripheral nervous systems. Ultimately, the fight-or-flight stress responses 
in the autonomic nervous system (ANS) or the defeat/withdrawal responses in the 
hypothalamic-pituitary-adrenal axis (HPA) are generated and secrete catecholamines and 
cortisol, respectively (Fig. 1).7,8 Activation of these pathways in acute stress are necessary 
for survival and are adaptive processes. In contrast, chronic stress negatively affects most 
physiological systems due to prolonged exposure to catecholamines and glucocorticoids.9
Chronic stress has been shown to decrease cellular immune parameters, such as natural 
killer (NK) cell cytotoxicity and T-cell responses to mitogen stimulation.10-12 Effects 
of biobehavioral factors on the immune system are thought to be mediated in part by 
the sympathetic nervous system, the HPA axis, and a variety of other hormones and 
peptides.13,14 To date, the majority of neuroendocrinological research dealing with stress 
and accelerated tumor growth has focused on suppressed immune response to malignant 
tissue.7 Recently, we and others have considered other biological pathways that may be 
affected by stress mediators. These observations are the focus of the current review.
neuroendocrIne InfLuenceS on cAncer
Tumorigenesis is a multistep process, and according to Hanahan and Weinberg, there 
are six essential acquired alterations in cell physiology that promote malignant growth: (1) 
self-sufficiency in growth signals, (2) insensitivity to anti-growth signals, (3) evasion of 
apoptosis, (4) limitless replicative potential, (5) sustained angiogenesis and (6) tissue inva-
sion and metastasis.15 After a cell acquires tumorigenic potential, then cancer metastasis can 
occur if another series of sequential interrelated steps including proliferation/angiogenesis, 
invasion, embolism/circulation, transport, adherence in organs, adherence to vessel wall 
and extravasation occur.16 Tumor progression is a result of crosstalk between different cell 
types within the tumor and its surrounding supporting tissue, tumor stroma and micro-
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and neurotransmitters, which are increased in certain biobehavioral 
states on the multistep process of cancer metastasis.
In order to proliferate, tumor cells rely on nutrient and oxygen 
diffusion. The effects of stress-related hormones on tumor cell prolif-
eration can be either stimulatory or inhibitory depending on the 
type of hormone and tumor type. For example, in breast carcinoma, 
activation of b-adrenergic receptors (ADRB) has been associated 
with accelerated tumor growth.18-20 In contrast, catecholamines may 
inhibit tumor cell proliferation that may be mediated by a-adrenergic 
receptors or the dopamine transporter. Scarparo and colleagues 
found that melanoma cells treated with the a1-adrenergic agonist 
phenylephrine led to a dose-dependent decrease in proliferation, 
which could be reversed by the a1-adrenergic antagonist prazosin.21 
Additionally, norepinephrine treatment shifted neuroblastoma cells 
expressing the dopamine transporter into the G0/G1 phase, thereby 
inhibiting proliferation.22 Similarly, the role of glucocorticoid 
hormones on proliferation is dual.23,24
The ability of a tumor cell to invade and metastasize to distant 
tissues is highly dependent on malignant cell adhesion to the extra-
cellular matrix.25 Enserink and colleagues have shown that the 
b-agonist isoproterenol promotes ovarian cancer cell spreading and 
adhesion via integrins through Epac (exchange factor directly acti-
vated by cAMP)-Rap1 pathway.26,27 Additionally, there is growing 
evidence that stress hormones may affect tumor cell motility and 
invasion. Norepinephrine has been shown to induce breast and 
colon cancer migration.28,29 We have previously demonstrated that 
physiologic stress concentrations of norepinephrine and epineph-
rine can enhance the invasive potential of ovarian carcinoma cells 
via the ADRB-mediated increases in matrix metalloproteinases 
(MMPs). The b-adrenergic antagonist propranolol and pharmaco-
logic blockade of MMPs abrogated the effects of norepinephrine on 
the increases in tumor cell invasive potential.30 This work provided 
the in vitro evidence that stress hormones can increase the invasive 
potential of ovarian cancer cells.
Avoidance of apoptosis is a critical component of the metastatic 
cascade. Thus far, glucocorticoids, which regulate a variety of cellular 
processes, have been the focus of research elucidating the role of 
stress hormones on tumor cell survival. Glucocorticoids downregulate 
proapoptotic elements of the death receptor and mitochondrial 
apoptosis pathways in cervical and lung cancer cell lines.31 Wu and 
colleagues found that breast cancer cell lines pretreated with dexameth-
asone inhibited chemotherapy-induced apoptosis via transcriptional 
induction of serum and GC-inducible protein kinase-1 (SGK-1) and 
mitogen activated protein kinase phosphatase-1 (MKP-1).32 The 
antiapoptotic effects of glucocorticoid treatment could be reversed by 
blockade of SGK-1 and MKP-1.32 Additionally, glucocorticoids and 
catecholamines may act synergistically to facilitate cancer growth as 
evidenced in lung carcinoma cell lines.33
Angiogenesis is a key process in the growth of most solid tumors 
beyond 1–2 mm in diameter, and their metastatic spread involves 
recruitment of nearby blood vessels to permeate the tumor.34 In 
vascular endothelial cells, ischemic neoangiogenesis causes prolifera-
tion via overexpression of the ADRB.35 Vascular endothelial growth 
factor (VEGF) is a key proangiogenic cytokine that is produced by 
tumor cells, endothelial cells, and platelets.36 We have previously 
reported that higher levels of social support were correlated with 
lower VEGF levels in serum from presurgical patients with ovarian 
carcinoma providing a possible mechanism by which poor social 
support may be associated with disease progression.37 We have also 
demonstrated that VEGF production by ovarian cancer cell lines 
was enhanced by stress hormones such as norepinephrine, epineph-
rine, and isoproterenol in vitro and blocked by the b-antagonist 
propranolol.38 Based on our previous studies, we sought to elucidate 
whether chronic stress and the associated increase in sympathetic 
nervous system activity had a causal effect on growth and metastasis 
of ovarian cancer in vivo.39
THe roLe of cHronIc STreSS on Tumor growTH         
And AngIogeneSIS In orTHoToPIc ovArIAn cArcInomA
We recently demonstrated that chronic stress (daily restraint) 
quantitated by elevated organ catecholamine (norepinephrine and 
cortisol) levels enhanced the pathogenesis of ovarian carcinoma 
in vivo, as evidenced by increased tumor weight and more invasive 
pattern of metastasis including parenchymal liver, spleen, and 
diaphragm involvement. Propranolol, a non-specific b-blocker, 
completely blocked the effects of immobilization stress on tumor 
growth, indicating a critical role for b-adrenergic signaling in stress 
mediated increases in tumor growth. The b-adrenergic receptors are 
G-protein-coupled receptors that mainly function to transmit extra-
cellular information to the interior of the cell, causing an activation of 
adenylyl cyclase and an accumulation of the second messenger cAMP 
to activate the protein kinase A pathway.40 Ultimately, after catechol-
amine stimulation, the activation of the tumor cell cAMP-protein 
kinase A signaling pathway led to increased VEGF gene expression, 
resulting in increased tumor vascularization and more aggressive 
growth. A series of experiments using either ADRB-null cell lines, 
Figure 1. Key components of the central and peripheral stress systems. In 
response to neurosensory signals, the hypothalamus secretes corticotro‑
phin‑releasing factor (CRF) and arginine vasopressin (AVP), which cause 
the pituitary to secrete adrenocorticotropic hormone (ACTH). Subsequently, 
ACTH promotes the production of glucocorticoids from the adrenal cortex. 
The sympathetic nervous system originates in the brain stem, and ultimately 
through post‑ganglionic fibers releases noradrenaline. The adrenal medulla 
releases mainly adrenaline. Reprinted with permission from Nature Reviews 
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pharmacological b-agonists, or ADRB-silencing with siRNA, demon-
strated that ADRB2 on the tumor cells plays a functionally significant 
role in stress-mediated angiogenesis. The increased angiogenesis 
occurred in response to increases in catecholamine induced VEGF 
production by tumor cells. The tumor vasculature in stressed animals 
contained more tortuous and numerous blood vessels than controls, 
and was accompanied by a significant decrease in the proportion of 
blood vessels with pericyte coverage in tumors from stressed animals, 
which suggests more immature vasculature. Additionally, magnetic 
resonance imaging and kinetic analysis of the stressed tumors showed 
substantial anatomical and functional alterations in tumor vasculature.
Both propranolol and VEGF blocker such as the VEGF-R2 
inhibitor PTK787 or the monoclonal VEGF-specific antibody 
bevacizumab completely blocked the stress induced effects on tumor 
burden and invasiveness. These results demonstrated that behavioral 
stressors can enhance the pathogenesis of ovarian carcinoma via 
VEGF-mediated angiogenesis in vivo (Fig. 2), and underscores the 
importance of the neuroendocrine system in cancer pathogenesis.
cLInIcAL oPPorTunITIeS And cHALLengeS
The knowledge of how stress biology affects tumor initiation and 
pathogenesis is gradually expanding. Biobehavioral factors such as 
chronic stress, depression, and social support have been linked to 
tumor biology via their endocrine consequences and cell mediated 
immunity. Although the molecular pathways have not been fully 
elucidated, the studies to date indicate possible opportunities for 
behavioral and pharmacological intervention that target tumor-sup-
porting neuroendocrine dynamics.
Pharmacologic and genetic manipulations identify b-adrenergic 
signaling as a central mediator of stress effects on cancer growth; 
therefore, pharmacological interventions such as b-blockers poten-
tially could be used to alleviate the effects of stress on cancer growth 
and progression. Interestingly, in a large case-control study of prostate 
cancer patients, Perron and colleagues found that among individuals 
taking anti-hypertensive medications, only b-blockers were associated 
with a reduction in cancer risk.41 A cohort study of cardiovascular 
patients that used b-blockers had a 49% decrease in cancer risk 
compared to patients that never used b-blockers. Moreover, there 
was a 6% decrease in risk for every additional year of b-blocker 
use.42 However, other population-based case-control studies of breast 
carcinoma patients have not confirmed alterations in risk with the 
use of b-blockers.43,44 The efficacy of b-blockers in blocking the 
stress-mediated effects on tumor remains to be examined.
To the extent that behavioral and central nervous system processes 
modulate the activity of multiple hormones45-48 and those processes are 
linked to angiogenic parameters in human clinical studies37,49 inter-
ventions targeting neuroendocrine function at the CNS level might 
also represent novel strategies for protecting cancer patients from the 
detrimental effects of stress biology on the progression of malignant 
disease. Such interventions may include behavioral interventions 
alone or in combination with pharmacological approaches.8
concLuSIonS
Although research has shown that stress hormones affect tumor 
pathogenesis at multiple levels (initiation, tumor growth, and metas-
tasis), our understanding of the underlying mechanisms is in its 
infancy and needs to be expanded. Based on the importance of the 
interplay between immunological and behavioral factors providing 
a favorable microenvironment for tumor initiation and growth, 
there is a crucial need to integrate a bio-behavioral perspective in 
therapeutic paradigms of human carcinoma. Interventions targeting 
neuroendocrine function at the level of the central nervous system 
could represent a novel strategy for protecting cancer patients 
from the deleterious effects of stress biology on cancer progression. 
Theoretically, these pharmacologic and behavioral interventions can 
be used concomitantly with conventional therapies to maximize effi-
cacy and warrant further study, especially as cancer treatment evolves 
to encompass more patient-specific therapeutic approaches.
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